Superworth

Insmed EPS INSM

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$4.11
Latest quarter, Q2 FY26
−$0.06
Fiscal year 2025
−$6.41

Insmed's earnings per share was −$4.11 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.06.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$6.41n/a
FY2024−$5.59n/a
FY2023−$5.34n/a
FY2022−$3.90n/a
FY2021−$3.87n/a
FY2020−$3.01n/a
FY2019−$3.04n/a
FY2018−$4.22n/a
FY2017−$2.86n/a
FY2016−$2.84n/a
FY2015−$2.03n/a
FY2014−$1.85n/a
FY2013−$1.58n/a
FY2012−$1.54n/a
FY2011−$2.97n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.06n/a−$4.11
Q1 FY26−$0.76n/a−$5.75
Q4 FY25−$1.54n/a−$6.41
Q3 FY25−$1.75n/a−$6.19
Q2 FY25−$1.70n/a−$5.71
Q1 FY25−$1.42n/a−$5.95
Q4 FY24−$1.32n/a−$5.59
Q3 FY24−$1.27n/a−$5.55
Q2 FY24−$1.94n/a−$5.39
Q1 FY24−$1.06n/a−$5.23
Q4 FY23−$1.28n/a−$5.34
Q3 FY23−$1.11n/a−$5.27

Against its peers

Companies in Biotechnology nearest Insmed's size, closest first, today.

CompanyEPS, 12 monthsGrowth
INSMInsmed−$4.11
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
EXELExelixis$3.18+53% a year
NBIXNeurocrine Biosciences$6.82+102% a year
HALOHalozyme Therapeutics$3.35−23% a year
ALNYAlnylam Pharmaceuticals$5.93
TECHBIO-TECHNE$1.15+150% a year
RGENRepligen$0.73
ONCBeOne Medicines$0.43
KRYSKrystal Biotech$7.98+62% a year
Peer median$4.64

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Insmed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.